T&L Records Subscription Competition Rate of 1109.2 to 1... Scheduled to List on KOSDAQ on the 20th

[Asia Economy Reporter Eunmo Koo] T&L has successfully completed its general subscription.

The high-performance medical material specialist T&L announced on the 16th that it recorded a competition rate of 1,109.19 to 1 in the public offering subscription for general investors held over two days from the 12th to the 13th. A total of 177,472,000 shares were applied for, targeting 160,000 shares, which is 20% of the total public offering volume. The subscription deposit amounted to approximately 3.1945 trillion KRW.

The company had previously set the public offering price at 36,000 KRW through a demand forecast for institutional investors. T&L will complete all public offering procedures with the payment of the subscription price on the 16th and plans to be listed on the KOSDAQ market on the 20th. The lead manager is Korea Investment & Securities.

T&L, which applies high-performance material technology to medical materials and operates a wound treatment material business, is evaluated to have secured stability, growth potential, and profitability through a strategic portfolio focused on high value-added products.

After listing, T&L plans to expand its production capacity by 1.5 times to meet market demand. A company official stated, “The high efficacy and healing effects of T&L products have been proven, and domestic and overseas orders continue, resulting in a situation where supply cannot keep up with demand.”

Furthermore, focusing on the rapidly growing U.S. market, T&L plans to expand its global network to China, Europe, and other regions, and strengthen growth engines by investing in facilities for new items such as hemostatic agents, smart patches, and microneedle patches.

Choi Yoon-so, CEO of T&L, said, “T&L’s high-performance material technology has been the core driving force that allowed us to gain an advantage in various convergent medical product markets such as fracture treatment fixatives, wound treatment materials, and trouble care patches,” adding, “We will strengthen our market-leading position through diversified premium product development and continue to grow soundly after listing.”